More intriguingly, current research has indicated that AQP4 protein aggregation state could be a determinant for glioma cell fate (Amiry-Moghaddam, 2019; Simone et al., 2019), strengthening the potential role of AQP4 as a target in the treatment of GBM. The gene discussed is AQP4; the disease is central nervous system cancer.